Publications

Members only publications are marked with a lock icon:
Filter By

Clinical Alerts
August 28, 2019
...
   
 

Black Box Warning About Fluoroquinolone Use

Clinical Alerts
September 7, 2018

FDA updates warnings for fluoroquinolone antibiotics on risks of mental health and low blood sugar adverse reactions at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm612995.htm

 The U.S. Food and Drug Administration (FDA) Recently Strengthened its Black Box Warning About Fluoroquinolone Use

 Appropriate fluoroquinolone prescribing is important for patient safety. A recent...

Nurse Assist Initiates Nationwide Voluntary Recall of All Unexpired Lots of I.V. Flush Syringes

Clinical Alerts
Infections
October 4, 2016

Nurse Assist, Inc. announced today that it is voluntarily recalling all unexpired lots of I.V. Flush Syringes due to a potential link to Burkholderia cepacia (B. cepacia) bloodstream infections with the product. Please click here for more information.

CDC Releases Making Health Care Safer - Sepsis Vital Signs

Clinical Alerts
Infections, Infection Prevention/Control
August 23, 2016

On August 23, 2016, the Centers for Disease Control and Prevention (CDC) released a report on sepsis that will focus on preventing infections that lead to sepsis and the importance of sepsis early recognition. The report will be release as part of CDC’s Vital Signs series, which focuses on critical public health issues. This monthly report CDC will include a scientific publication (MMWR), a 4-page plain language graphic fact sheet, website, media release, and social media tools. For more information, click here.

Multistate Outbreak of Burkholderia cepacia Infections - 8/10 Update

Clinical Alerts
Infections, Medication
August 10, 2016

FDA released an updated statement including a voluntary recallExternal Web Site Icon of all of liquid products manufactured by PharmaTech and distributed by: Rugby, Major, Bayshore, Metron, Centurion, and Virtus. Read more.

Policy Statement on Pneumococcal Vaccination

Clinical Alerts
Health Maintenance, Infections, Immunization/Vaccination, Pneumonia
July 20, 2016

Background:

Pneumococcal disease is known to have a potentially serious impact in frail individuals, particularly those residing in post-acute and long-term care settings where outbreaks have been demonstrated and which could have been prevented by adequate vaccination.

Two pneumococcal vaccines are currently licensed and readily available in the United States.

The Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) has conducted an extensive evaluation use of these vaccines in adults, demonstrating...

Multistate Outbreak of Burkholderia cepacia Infections - UPDATE 7/18

Clinical Alerts
Infections, Medication
July 18, 2016

Case count corrected as of July 18, 2016. CDC has confirmed 49 cases from 5 states. Read more.

Multistate Outbreak of Burkholderia cepacia Infections - UPDATE 7/16

Clinical Alerts
Infections, Medication
July 16, 2016

FDA has released a statement regarding a voluntary recallExternal Web Site Icon of certain liquid docusate products. The extent of this issue remains under investigation; therefore, both FDA and CDC continue to recommend that clinicians and patients not use any liquid docusate sodium product as a stool softener or for any other medical purpose. Read more.

Multistate Outbreak of Burkholderia cepacia Infections

Clinical Alerts
Infections, Medication
July 8, 2016

The CDC is collaborating with the Food and Drug Administration (FDA), multiple state and local health departments, and healthcare facilities to investigate a multi-state outbreak of Burkholderia cepacia infections. These infections have occurred primarily in ventilated patients without cystic fibrosis and who are being treated in intensive care units. A CDC July 8, 2016 update continues to recommend that clinicians not use any liquid docusate product as a stool softener or for any other medical purpose.

The recommendation has expanded from not using liquid docusate products for...

FDA Alert: Fluoroquinolone Antibacterial Drugs: Drug Safety Communication - FDA Advises Restricting Use for Certain Uncomplicated Infections

Clinical Alerts
Antimicrobial/Antibiotic Stewardship, Medication, Antibiotics/Antimicrobials
May 12, 2016

The U.S. Food and Drug Administration is advising that the serious side effects associated with fluoroquinolone antibacterial drugs generally outweigh the benefits for patients with sinusitis, bronchitis, and uncomplicated urinary tract infections who have other treatment options. For patients with these conditions, fluoroquinolones should be reserved for those who do not have alternative treatment options...